Arrhythmic Gut Microbiome Signatures Predict Risk of Type 2 Diabetes.


Journal

Cell host & microbe
ISSN: 1934-6069
Titre abrégé: Cell Host Microbe
Pays: United States
ID NLM: 101302316

Informations de publication

Date de publication:
12 08 2020
Historique:
received: 23 02 2020
revised: 08 05 2020
accepted: 08 06 2020
pubmed: 4 7 2020
medline: 13 5 2021
entrez: 4 7 2020
Statut: ppublish

Résumé

Lifestyle, obesity, and the gut microbiome are important risk factors for metabolic disorders. We demonstrate in 1,976 subjects of a German population cohort (KORA) that specific microbiota members show 24-h oscillations in their relative abundance and identified 13 taxa with disrupted rhythmicity in type 2 diabetes (T2D). Cross-validated prediction models based on this signature similarly classified T2D. In an independent cohort (FoCus), disruption of microbial oscillation and the model for T2D classification was confirmed in 1,363 subjects. This arrhythmic risk signature was able to predict T2D in 699 KORA subjects 5 years after initial sampling, being most effective in combination with BMI. Shotgun metagenomic analysis functionally linked 26 metabolic pathways to the diurnal oscillation of gut bacteria. Thus, a cohort-specific risk pattern of arrhythmic taxa enables classification and prediction of T2D, suggesting a functional link between circadian rhythms and the microbiome in metabolic diseases.

Identifiants

pubmed: 32619440
pii: S1931-3128(20)30343-7
doi: 10.1016/j.chom.2020.06.004
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

258-272.e6

Subventions

Organisme : Medical Research Council
ID : MR/N030125/1
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Interests The authors declare no competing interests.

Auteurs

Sandra Reitmeier (S)

ZIEL - Institute for Food & Health, Technical University of Munich, 85354 Freising, Germany; Chair of Nutrition and Immunology, Technical University of Munich, Gregor-Mendel-Str. 2, 85354 Freising, Germany.

Silke Kiessling (S)

ZIEL - Institute for Food & Health, Technical University of Munich, 85354 Freising, Germany; Chair of Nutrition and Immunology, Technical University of Munich, Gregor-Mendel-Str. 2, 85354 Freising, Germany.

Thomas Clavel (T)

ZIEL - Institute for Food & Health, Technical University of Munich, 85354 Freising, Germany; Functional Microbiome Research Group, Institute of Medical Microbiology, RWTH University Hospital, Pauwelsstraße 30, 52074 Aachen, Germany.

Markus List (M)

Chair of Experimental Bioinformatics, Technical University of Munich, Maximus-von-Imhof-Forum 3, 85354 Freising, Germany.

Eduardo L Almeida (EL)

School of Microbiology and APC Microbiome Ireland, University College Cork, Ireland.

Tarini S Ghosh (TS)

School of Microbiology and APC Microbiome Ireland, University College Cork, Ireland.

Klaus Neuhaus (K)

ZIEL - Institute for Food & Health, Technical University of Munich, 85354 Freising, Germany.

Harald Grallert (H)

Helmholtz Zentrum München and German Diabetes Center (DDZ), Ingolstaedter Landstr. 1, 85764 Oberschleißheim.

Jakob Linseisen (J)

Helmholtz Zentrum München and German Diabetes Center (DDZ), Ingolstaedter Landstr. 1, 85764 Oberschleißheim; Chair of Epidemiology, Ludwig-Maximilians University, UNIKA-T Augsburg, Neusässer Str. 47, 86156 Augsburg, Germany.

Thomas Skurk (T)

ZIEL - Institute for Food & Health, Technical University of Munich, 85354 Freising, Germany.

Beate Brandl (B)

ZIEL - Institute for Food & Health, Technical University of Munich, 85354 Freising, Germany.

Taylor A Breuninger (TA)

Helmholtz Zentrum München and German Diabetes Center (DDZ), Ingolstaedter Landstr. 1, 85764 Oberschleißheim.

Martina Troll (M)

Helmholtz Zentrum München and German Diabetes Center (DDZ), Ingolstaedter Landstr. 1, 85764 Oberschleißheim.

Wolfgang Rathmann (W)

German Diabetes Center (DDZ) and German Center for Diabetes Research (DZD e.V.), Auf'm Hennekamp 65, 40225 Dusseldorf, Germany.

Birgit Linkohr (B)

Helmholtz Zentrum München and German Diabetes Center (DDZ), Ingolstaedter Landstr. 1, 85764 Oberschleißheim.

Hans Hauner (H)

ZIEL - Institute for Food & Health, Technical University of Munich, 85354 Freising, Germany; Institute of Nutritional Medicine, Technical University of Munich, Georg-Brauchle-Ring 62, 80992 Munich, Germany.

Matthias Laudes (M)

Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, Rosalind-Franklin-Straße 12, 24105 Kiel, Germany; Division of Endocrinology, Diabetes and Clinical Nutrition, Department of Medicine, University of Kiel, 24105 Kiel, Germany.

Andre Franke (A)

Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, Rosalind-Franklin-Straße 12, 24105 Kiel, Germany.

Caroline I Le Roy (CI)

Department of Twin Research & Genetic Epidemiology, King's College London, Strand, London WC2R 2LS, UK.

Jordana T Bell (JT)

Department of Twin Research & Genetic Epidemiology, King's College London, Strand, London WC2R 2LS, UK.

Tim Spector (T)

Department of Twin Research & Genetic Epidemiology, King's College London, Strand, London WC2R 2LS, UK.

Jan Baumbach (J)

Chair of Experimental Bioinformatics, Technical University of Munich, Maximus-von-Imhof-Forum 3, 85354 Freising, Germany.

Paul W O'Toole (PW)

School of Microbiology and APC Microbiome Ireland, University College Cork, Ireland.

Annette Peters (A)

Helmholtz Zentrum München and German Diabetes Center (DDZ), Ingolstaedter Landstr. 1, 85764 Oberschleißheim; Chair of Epidemiology, Ludwig-Maximilians University, Marchioninistr. 15, 81377 Munich, Germany.

Dirk Haller (D)

ZIEL - Institute for Food & Health, Technical University of Munich, 85354 Freising, Germany; Chair of Nutrition and Immunology, Technical University of Munich, Gregor-Mendel-Str. 2, 85354 Freising, Germany. Electronic address: dirk.haller@tum.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH